Advances in immunology, Journal Year: 2024, Volume and Issue: unknown
Published: Jan. 1, 2024
Language: Английский
Vaccines, Journal Year: 2024, Volume and Issue: 12(3), P. 259 - 259
Published: March 1, 2024
Various vaccine platforms, including emerging have been applied in the development of COVID-19 vaccines. Biotechnology startups often lead new medical technologies, whereas major pharmaceutical companies and public institutions long contributed to development. In this study, platforms developers involved were analyzed, elucidating trends used, country distribution developers, differences profiles by platform technologies country. The analysis revealed that conventional, established, widely used older are more advanced clinical It also demonstrated emergence China, addition U.S., while many pharmerging countries engaged Startups significantly viral vector RNA-based vaccines, suggesting their important role application novel technologies. differ region. Alliances, international collaborations, progressed late Based on these results, future perspectives pandemic implications for policy corporate strategies discussed.
Language: Английский
Citations
8
Vaccines, Journal Year: 2025, Volume and Issue: 13(3), P. 312 - 312
Published: March 13, 2025
Background/Objectives: Although the COVID-19 pandemic has largely concluded, varied trajectories it followed in different regions of world remain incompletely understood. Intensive research is needed to fully grasp its course and implications for future global health challenges. Notably, milder trajectory Sub-Saharan Africa defied initial predictions. An emerging body evidence suggests that, addition continent’s younger average age lower prevalence relevant comorbidities, co-infections with helminths may have also impressively shaped pandemic’s region. Indeed, are renowned their ability modulate human immune responses, which, while potentially beneficial limiting excessive inflammation, could diminish vaccine efficacy impede viral clearance. This study investigated aspects intricate interactions between Lymphatic Filariasis (LF), a helminth infection caused by parasitic worms such as Wuchereria bancrofti, Brugia malayi, timori endemic various tropics. Methods: For this purpose, samples larger ongoing clinical trial (ethical approval codes: CHRPE/AP/525/17 325/21; registration number ISRCTN14042737) were collected from 222 individuals areas Ghana, along comprehensive demographic data. The include LF patients (n = 222) grouped according Lymphoedema (LE) stages, well vaccinated 81) non-vaccinated 141). All participants received ChAdOx1-S (also known Vaxzevria) developed University Oxford AstraZenca. expressions SARS-CoV-2 filarial-specific antibodies (IgG, IgA) accessed using ELISA, Luminex-based immunoassays employed measure expression variant-specific neutralizing antibodies. interplay responses factors was analyzed group comparisons Kruskal-Wallis or Mann-Whitney U tests. Results: results indicate that remarkable portion unvaccinated (56% IgA seropositive, 39% IgG seropositive) against despite no confirmed infection. identified robust antibody response vaccination, which independent degree pathology status. important observation reduced seropositive Ascaris lumbricoides (p 0.0264), highlighting an interaction roundworm COVID-19. Conclusions: concludes (AstraZeneca) triggers strong patients; however, filarial and/or soil-transmitted seropositivity might influence infection-induced response. These findings emphasize complexity infectious disease dynamics co-infected populations need decipher parasite-induced immunomodulatory mechanisms on vaccination.
Language: Английский
Citations
0
Pharmacology Research & Perspectives, Journal Year: 2025, Volume and Issue: 13(3)
Published: April 27, 2025
ABSTRACT In Japan, biopharmaceutical startups have not been sufficiently nurtured, leading to weak international competitiveness in new drug development. This is partly due low levels of entrepreneurship the private sector and limited investment startups. Therefore, it crucial for Japanese government provide financial support study aims offer a comprehensive overview current state grants investments as well discuss associated challenges future directions. Both grant programs specifically focused on discovery development those supporting broader range industries, including development, were identified through literature reviews web searches. Advisory affiliated with agencies that assist also identified. Additionally, has established national university funds at four universities, which made While offers various different stages research relatively small scale these seed‐stage projects pose significant challenges. Consulting services provided by government, advice strategies processes, particularly beneficial researchers Japan who lack expertise However, some initiatives spread across ministries, highlighting need more unified approach.
Language: Английский
Citations
0
YAKUGAKU ZASSHI, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Establishing a robust drug discovery ecosystem is seen as key priority for enhancing Japan's capabilities. Globally, startups play significant role in advancing discovery. The author's research demonstrated that have recently expanded their to late-entry discovery, the area where large pharmaceutical companies traditionally had strength, while maintaining contribution first-in-target Despite growing importance of startups, Japan has faced challenges fostering successful falling particularly behind leveraging modality technologies. development promising requires establishment startup ecosystem, U.S. and certain European countries. supporting remains fragile due factors such low entrepreneurial activity, limited labor mobility, insufficient investment capital. revealed unlisted "being corporate spin-off" "having leader with prior experience R&D" positively impact startup's valuation total funding amounts. In Japan, still account majority new discoveries, wealth seeds experienced R&D talent accumulated within these corporations. Facilitating creation spin-offs utilize unexploited promoting transfer could strengthen ecosystem. This paper will also explore potential policy measures encourage developments.
Language: Английский
Citations
0
Vaccines, Journal Year: 2025, Volume and Issue: 13(4), P. 406 - 406
Published: April 14, 2025
This review systematically revises adenovirus (Ad) biology, vector structure, immune responses, and currently available Ad COVID-19 vaccines. It analyzes the challenges associated with vector-based vaccines, including preexisting immunity other side effects. Moreover, this explores novel innovative strategies to overcome these constraints for developing next-generation vaccines broad protection cover emerging SARS-CoV-2 variants. The future refinement of vaccine platforms will be pivotal in achieving durable against variants global preparedness.
Language: Английский
Citations
0
Vaccine, Journal Year: 2025, Volume and Issue: 59, P. 127271 - 127271
Published: May 23, 2025
Contribution of Developing Countries Vaccine Manufacturers (DCVMs) in the vaccine response to COVID-19 pandemic crisis 2021-2022 has been paramount, totaling 9.81 billion 15.91 doses distributed [1]. However, since many DCVMs acted as licensees or contract-manufacturing organizations (CMOs) alternate developers, global understanding and knowledge magnitude this contribution is understated. This paper aims at documenting analyzing further details critical central role played by tackle pandemic.
Language: Английский
Citations
0
npj Vaccines, Journal Year: 2025, Volume and Issue: 10(1)
Published: May 24, 2025
This review examines Moderna's mRNA-1083 and Pfizer/BioNTech's mRNA-1020/1030 dual-target vaccines for COVID-19 influenza. Both utilize mRNA technology, demonstrating strong immunogenicity favorable safety profiles. showed superior immune responses, while Pfizer's performed well but was slightly less effective against influenza B. These simplify immunization strategies, enhance protection, emphasize the need global vaccine equity to prevent future outbreaks.
Language: Английский
Citations
0
Vaccines, Journal Year: 2024, Volume and Issue: 12(7), P. 792 - 792
Published: July 18, 2024
Several technological approaches have been used to develop vaccines against COVID-19, including those based on inactivated viruses, viral vectors, and mRNA. This study aimed monitor the maintenance of anti-SARS-CoV-2 antibodies in individuals from Brazil according primary vaccination regimen, as follows: BNT162b2 (group 1; 22) ChAdOx1 2; 18). Everyone received first booster while second CoronaVac, Ad26.COV2.S, or BNT162b2. Blood samples were collected 2021 2023 analyze specific RBD (ELISA) neutralizing (PRNT50). We observed a progressive increase anti-RBD each subsequent dose, remaining at high titers until end follow-up. Group 1 had higher antibody than group 2 after beginning with significant differences 2nd 3rd doses. showed more expressive BNT162B2 (heterologous booster). also presented levels Gamma Delta variants five months booster. In conclusion, circulating two SARS-CoV-2 durable even 4th suggesting that periodic vaccinations (homologous heterologous) induced long-lasting immunity.
Language: Английский
Citations
2
Cureus, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 9, 2024
Background and aim The COVID-19 pandemic has globally impacted all sectors. Early vaccine development was crucial to curb the spread of virus. However, concerns about safety side effects have led hesitancy. This study aims examine compare associated with Pfizer/BioNTech, Oxford/AstraZeneca, Sinopharm vaccines in Iraqi Kurdistan. Materials methods A population-based conducted Kurdistan Region Iraq from September 2022 April 2023, involving 1,340 participants recruited through face-to-face interviews online forms. questionnaire collected demographic data information on infection vaccination status. Results Among participants, 52.76% were females, a mean age 29.21 years (±13.09 SD). Of these, 67.84% received Pfizer/BioNTech vaccine, 60.9% had prior infection. About 76.94% experienced post-vaccination effects, lasting an average 2.8 days (±1.92 Notably, 60% reported no or mild effects. Common across included injection site pain, fever, headache, fatigue. Side more frequent after first dose highest followed by (p = 0.001). Higher rates observed aged 36-60, married individuals, those chronic conditions, previously infected who contracted Conclusions reveals that most either only reactions following vaccination, none being serious. These findings are expected boost public confidence increase uptake, especially booster doses now available.
Language: Английский
Citations
1
Clinical and Experimental Medicine, Journal Year: 2024, Volume and Issue: 25(1)
Published: Dec. 25, 2024
Abstract Decades of basic and translational research have led to a momentum shift in dissecting the relationship between immune cells cancer. This culminated emergence breakthrough immunotherapies that paved way for oncologists manage certain hard-to-treat cancers. The application high-throughput techniques genomics, transcriptomics, proteomics was conclusive making expediting manufacturing process cancer vaccines. Using latest technologies has also enabled scientists interpret complex multiomics data tumour mutanome, thus identifying new tumour-specific antigens design generations vaccines with high specificity long-term efficacy. Furthermore, combinatorial regimens checkpoint inhibitors offered therapeutic approaches demonstrated impressive efficacy patients over last few years. In present review, we summarize current state vaccines, including their potential effects limitations hinder effectiveness. We highlight efforts mitigate these ongoing clinical trials. Finally, special focus will be given milestones expected transform landscape therapy nurture hope among patients.
Language: Английский
Citations
1